Bringing the fundamentals into focus…
Back to Lyell Immunopharma, Inc.
How Lyell Immunopharma, Inc. stacks up
LYEL · against 290 other Healthcare companies of similar size
Growth
5/ 100
Near the bottom of its peers.
Ranked #270 of 291 · scores higher than 7% of peers
Bars: peers in each 10-point band of the growth score42 peers with a growth score of 0–9, including LYEL · Click a bar to see the companies
Why growth scores 5?
Weighted metrics compared with all Healthcare companies.Mainly because of its 3-year revenue growth and revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over three years: weaker than 100% of peers. 3-year revenue growth: -91.8% vs peer median 5.8%
- slower revenue growth over the last year: weaker than 96% of peers. Revenue growth: -55.0% vs peer median 6.1%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = LYEL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LYEL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 305 reported | -55.0% | 3.0% | 6% | 33% | |
| Earnings per share growthHigher is better · 134 reported | Not reported | 4.1% | — | — | 33% |
| 3-year revenue growthHigher is better · 283 reported | -91.8% | 3.9% | 0% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around LYEL| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 2 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 2 | 592M ILS (≈$160M) | 99 | 84 | |
| 2 | 433M USD | 99 | 81 | |
| 266 | 3.2B CNY (≈$449M) | 6 | 35 | |
| 266 | 2.5B CNY (≈$346M) | 6 | 45 | |
| 266 | 2.91T IDR (≈$180M) | 6 | 50 | |
| 270 | 2.1B CNY (≈$290M) | 5 | 27 | |
| 270 | 264M USD | 5 | 24 | |
| 272 | 3.6B CNY (≈$506M) | 4 | 39 | |
| 272 | 1.9B CNY (≈$270M) | 4 | 44 | |
| 272 | 320M USD | 4 | 44 | |
| 272 | 223M USD | 4 | 34 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score